Abatacept Biosimilar

Abatacept Biosimilar

$400.00$1,600.00

In stock

$400.00$1,600.00

Abatacept Biosimilar. Orencia biosimilar CHO stable cell line is available for licensing to manufacture the abatacept biosimilar protein.The research grade abatacept biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls and recombinant hIgG1 Fc proteins are available.

SKU: C007P
Clear
View cart
Catalog No. C007P
Product NameAbatacept Biosimilar
Supplier Name Syd Labs, Inc.
Brand Name Syd Labs
Synonyms Orencia, CTLA-4 Fc Fusion Protein
Summary Recombinant protein composed of the extracellular domain of CTLA-4 fused with the Fc region of human immunoglobulin gamma 1 (hIgG1).
Source/Host The abatacept biosimilar protein was produced in the Orencia biosimilar CHO stable cell line.
Specificity/Sensitivity The abatacept biosimilar protein specifically binds to the human CD80 (B7-1) with more avidity than to CD86 (B7-2).
Form Of Antibody 0.2 uM filtered solution, pH 6.8 to 7.4, no stabilizers or preservatives.
Endotoxin <1 EU/mg of the protein by the LAL method.
Purity >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping The abatacept biosimilar protein is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note Orencia biosimilar CHO stable cell line is available for licensing to manufacture the abatacept biosimilar protein.The research grade abatacept biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls and recombinant hIgG1 Fc proteins are available.
Order Offline Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C007P: Abatacept Biosimilar

Recombinant protein composed of the extracellular domain of CTLA-4 fused with the Fc region of human immunoglobulin gamma 1 (hIgG1).

Abatacept (trade name Orencia, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Abatacept binds to CD80 (B7-1) with more avidity than to CD86 (B7-2). Abatacept inhibits the costimulation of T cells. Abatacept differs from belatacept (trade name Nulojix) by only 2 amino acids.

The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation.

Syd Labs also provides the following CTLA-4 Fc Fusion Protein biosimilar:
Belatacept Biosimilar

Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody

Please remember our product information: Abatacept Biosimilar: C007P Syd Labs

Additional information

Ship from Country

USA

Size

1 mg, 20 mg, 5 mg

No more offers for this product!